{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T07:54:51Z","timestamp":1697874891906},"reference-count":43,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p>Desde a introdu\u00e7\u00e3o das medica\u00e7\u00f5es antipsic\u00f3ticas at\u00edpicas, iniciando com a clozapina, em 1990, muitos relatos associam essas drogas ao desenvolvimento de diabetes mellitus, entre outros dist\u00farbios metab\u00f3licos, assim como abertura da doen\u00e7a como cetoacidose. Relatamos o caso de um paciente de 28 anos, com esquizofrenia, admitido em cetoacidose diab\u00e9tica 1 m\u00eas ap\u00f3s in\u00edcio da terapia com clozapina, sem rela\u00e7\u00e3o com ganho de peso, mantendo-se com n\u00edveis satisfat\u00f3rios de glicemia, sem tratamento, ap\u00f3s suspens\u00e3o da droga. Revisamos o assunto, com outros casos relatados at\u00e9 o momento, incluindo a associa\u00e7\u00e3o de outros antipsic\u00f3ticos at\u00edpicos igualmente envolvidos em dist\u00farbios end\u00f3crinos. Objetivamos, com o relato deste caso, aumentar a aten\u00e7\u00e3o dos cl\u00ednicos envolvidos no tratamento dos pacientes portadores de dist\u00farbios psiqui\u00e1tricos para a possibilidade do surgimento de diabetes durante a terapia, e enfatizar a necessidade de aumento da vigil\u00e2ncia e do acompanhamento metab\u00f3lico desses pacientes.<\/jats:p>","DOI":"10.1590\/s0004-27302007000300019","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T03:16:00Z","timestamp":1195182960000},"page":"488-493","source":"Crossref","is-referenced-by-count":5,"title":["Diabetes mellitus associado com drogas antipsic\u00f3ticas at\u00edpicas: relato de caso e revis\u00e3o da literatura"],"prefix":"10.1590","volume":"51","author":[{"given":"Janice Sep\u00falveda","family":"Reis","sequence":"first","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Alvarenga","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Weslley S. do","family":"Ros\u00e1rio","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia A.F.C.","family":"Menezes","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta dos Santos","family":"Rocha","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulo","family":"Purisch","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson GD","year":"1997","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo: Seroquel Study Group","volume":"54","author":"Small JG","year":"1997","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder SR","year":"1994","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff DC","year":"1998","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref6","first-page":"137","article-title":"Glucose tolerance in schizophrenia","volume":"44","author":"Ward JI","year":"1972","journal-title":"Orthomol Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0317-0217","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0010-440X(96)90054-1","article-title":"Diabetes mellitus in schizophrenic patients","volume":"37","author":"Mukherjee S","year":"1996","journal-title":"Compr Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0010-440X","issn-type":"print"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2005-871245","article-title":"Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report","volume":"38","author":"Takahashi M","year":"2005","journal-title":"Pharmacopsychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0031-7098","issn-type":"print"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1176\/appi.psy.42.3.279","article-title":"Risperidone-associated diabetic ketoacidosis","volume":"42","author":"Haupt DW","year":"2001","journal-title":"Psychosomatics","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3182","issn-type":"print"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal MM","year":"2003","journal-title":"Ann Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/1040-1237","issn-type":"print"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1176\/ajp.153.6.817","article-title":"Differential effect of clozapine on weight: a controlled study","volume":"153","author":"Bustillo JR","year":"1996","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses","volume":"170","author":"Melkersson KI","year":"2003","journal-title":"Psychopharmacology (Berl)","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002130000639","article-title":"Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents","volume":"154","author":"Melkersson KI","year":"2001","journal-title":"Psychopharmacology (Berl)","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson DC","year":"2000","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4088\/JCP.v59n0604","article-title":"Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications","volume":"59","author":"Hagg S","year":"1998","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(01)01000-2","article-title":"Clozapine-associated diabetes","volume":"111","author":"Koller E","year":"2001","journal-title":"Am J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new-onset diabetes","volume":"44","author":"Wirshing DA","year":"1998","journal-title":"Biol Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1176\/appi.psy.44.3.249","article-title":"Low-dose clozapine and diabetic ketoacidosis","volume":"44","author":"Lafayette JM","year":"2003","journal-title":"Psychosomatics","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3182","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing DA","year":"2002","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1176\/ajp.156.8.1270","article-title":"Clozapine-associated elevation in serum triglycerides","volume":"156","author":"Gaulin BD","year":"1999","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002826-199903000-00006","article-title":"The impact of clozapine treatment on serum lipids in chronic schizophrenic patients","volume":"22","author":"Spivak B","year":"1999","journal-title":"Clin Neuropharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0362-5664","issn-type":"print"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","article-title":"Olanzapine: weight gain and therapeutic efficacy","volume":"19","author":"Gupta S","year":"1999","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison DB","year":"1999","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","article-title":"Olanzapine induces insulin resistance: results from a prospective study","volume":"64","author":"Ebenbichler CF","year":"2003","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"Melkersson KI","year":"2000","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","article-title":"Olanzapine-associated diabetes mellitus [review]","volume":"22","author":"Koller EA","year":"2002","journal-title":"Pharmacotherapy","ISSN":"http:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"key":"ref27","first-page":"1","article-title":"Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature [review]","volume":"19","year":"2005","journal-title":"CNS Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000064807","article-title":"Atypical antipsychotic drug use and diabetes","volume":"71","author":"Ananth J","year":"2002","journal-title":"Psychother Psychosom","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3190","issn-type":"print"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1592\/phco.23.6.735.32178","article-title":"Risperidone-associated diabetes mellitus: a pharmacovigilance study","volume":"23","author":"Koller EA","year":"2003","journal-title":"Pharmacotherapy","ISSN":"http:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1176\/appi.psy.42.3.279","article-title":"Risperidone-associated diabetic ketoacidosis","volume":"42","author":"Haupt DW","year":"2001","journal-title":"Psychosomatics","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3182","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00331-0","article-title":"New-onset diabetes and ketoacidosis with atypical antipsychotics","volume":"59","author":"Wilson DR","year":"2002","journal-title":"Schizophr Res","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.jcp.0000085404.08426.3a","article-title":"Antipsychotic-induced type 2 diabetes: evidence from a large health plan database","volume":"23","author":"Gianfrancesco F","year":"2003","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"Koro CE","year":"2002","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"Atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia","volume":"16","author":"Borison R","year":"1996","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4088\/JCP.v65n0619","article-title":"A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus","volume":"65","author":"Koller EA","year":"2004","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00004714-200108000-00003","article-title":"Novel antipsychotics and severe hyperlipidemia","volume":"21","author":"Meyer JM","year":"2001","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00004583-200205000-00004","article-title":"Quetiapine-associated hyperglycemia and hypertriglyceridemia [letter]","volume":"41","author":"Domon SE","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0890-8567","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials","volume":"61","author":"Marder SR","year":"2003","journal-title":"Schizophr Res","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"1-2","key":"ref39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(01)03026-8","article-title":"Inhibition of glucose transport in PC12 cells by atypical antipsychotic drugs risperidone and clozapine and structural analogs of clozapine","volume":"27","author":"Ardizzone TD","year":"2001","journal-title":"Brain Res","ISSN":"http:\/\/id.crossref.org\/issn\/0006-8993","issn-type":"print"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1592\/phco.23.10.1123.32759","article-title":"Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration\u2019s MedWatch surveillance system and published reports","volume":"23","author":"Koller EA","year":"2003","journal-title":"Pharmacotherapy","ISSN":"http:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1464-5491.2000.00296.x","article-title":"Diabetes as a result of atypical anti-psychotic drugs-a report of three cases","volume":"17","author":"Rigalleau V","year":"2000","journal-title":"Diabet Med","ISSN":"http:\/\/id.crossref.org\/issn\/0742-3071","issn-type":"print"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v51n3\/a19v51n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T19:17:56Z","timestamp":1684091876000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302007000300019&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0004-27302007000300019"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302007000300019","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}